Standardize the pathway, personalize the adjustment. It sounds almost too simple to be the answer. But that architecture, borrowed directly from oncology, is the actual unlock for practices trying to scale past the two-hundred-patient ceiling and there are a few specific places practitioners tend to get the borrowing wrong.

The custom-everything trap, and why it feels like good medicine

Most practitioners who cap out around two hundred patients aren’t failing at medicine. They’re succeeding at the wrong version of it. Building a fully bespoke plan for every patient feels like the highest standard of care you can offer, and for a panel of fifty patients, it might be. The problem shows up at patient three hundred, when the clinician is still the only node every decision routes through, and there are only so many hours in a week.

Oncology hit this exact wall generations ago. No oncologist invents a new chemotherapy regimen from scratch for every patient. There’s a protocol, built from population-level evidence, and the protocol is adjusted to the individual’s markers, staging, and response. The personalization lives in the adjustment, not in the architecture. That’s the whole borrowing.

What actually gets standardized (and what doesn’t)

This is the part that’s easy to misread. Standardizing the pathway does not mean treating every patient identically. It means every patient enters the same intake, moves through the same three pathways, and the route and dosage through those pathways is set by their diagnostics.

Pathway one (foundational health) is protocolized with hard, measurable targets: VO2 max above the 75th percentile for age, hs-CRP under 1.0, HbA1c under 5.4, Sleep Regularity Index above 80. Every patient gets this pathway. What differs is the specific program a patient’s data points them toward, not whether they’re on it.

Pathway two (pharmacologic optimization) standardizes the decision rules, not the prescription. GLP-1 agonists in indicated metabolic patients. Statins or PCSK9 inhibitors when APOB and Lp(a) say so. The rule is fixed. The output depends entirely on the individual’s markers.

Pathway three (advanced, targeted therapies) is where the standardization is strictest in one specific way: it’s never the entry point. Peptides, NAD+ precursors, senolytics, all of it sits on top of a patient who has already worked through pathways one and two. That ordering is the clinical guardrail that keeps this from turning into a supplement counter with a medical license attached.

A composite example, because the abstraction is easier to see in practice

Picture a patient whose diagnostics show elevated Lp(a), borderline HbA1c, and VO2 max in the 40th percentile for her age. Pathway one puts her on a specific aerobic and resistance protocol targeted at the VO2 max gap, with nutrition adjustments aimed at the HbA1c number. Pathway two flags her Lp(a) for a conversation about PCSK9 inhibition, per the marker-driven decision rule, not by default. Pathway three doesn’t come up yet, because she hasn’t earned her way there. Six months later, if her foundational markers have moved and a documented deficiency shows up, a peptide protocol becomes a reasonable next layer. Nothing here required inventing a plan from scratch. It required reading her data against a framework that already existed.

The mistake that undoes all of this

The single most common way practitioners break this model is skipping straight to pathway three because it’s the part patients ask about first. Rapamycin, peptides, and senolytics get the attention online, and patients will ask for them by name before they’ve done a single sleep or nutrition intervention. Holding the line, foundational work first, pharmacologic optimization second, advanced therapies only on a stabilized system, is what keeps the model both safe and scalable. It’s also, not incidentally, what keeps you defensible if a regulator or a plaintiff’s attorney ever asks why a patient was on rapamycin.

Where this goes next

Protocols only scale if something other than the physician is running them day to day. The next piece in this series covers the two pillars that make that possible: the technology stack that monitors continuously, and the multidisciplinary team that delivers pathway one without the physician in every interaction.